INTRODUCTION AND OBJECTIVES:
Pellethane is an aromatic polyether-based thermoplastic polyurethane noted for its strength, flexibility, and resistance to solvents. No studies have assessed the encrustation properties of Pellethane and surface-treated Pellethanes in urine. In an effort to identify a better material for ureteral stents, we sought to assess the stability in artificial urine (AU) (Ward 0 s Scienceâ) of uncoated Pellethane and Pellethane surface-grafted with either 2-hydroxyethyl methacrylate (HEMA), a hydrogel, or tetraethylene glycol dimethyl ether (tetraglyme), both of which have the ability to resist protein adsorption.
METHODS: In a batch-flow AU model (Figure 1 ), Pellethane, HEMA-grafted Pellethane, and tetraglyme-grafted Pellethane, were tested against a commercially available hydrogel-coated latex urinary catheter (Bardâ) and a hydrophilic polymer-coated polyurethane ureteral stent (Cook Medicalâ). Encrustation was quantified by the change in dry weight. Cylindrical samples of comparable mass were weighed prior to suspension in AU; 3-day, 7-day, and 30-day immersion trials were conducted. AU solution refresh was done on alternating days. Samples were dried for 48 hours in a fume hood prior to being weighed.
RESULTS: Pellethane products exhibited less mass increase than the commercially available catheter or stent (Table 1) . At the conclusion of the 30-day trial, the mass changes were: catheter, +6.40%; stent, +8.63%; uncoated Pellethane, +0.58%; HEMA-grafted Pellethane, +0.07%; and tetraglyme-grafted Pellethane, -0.76%. The tetraglyme-coated Pellethane may have lost mass due to extraction of components from the tetraglyme coating in AUS.
CONCLUSIONS: Compared to commercially available urinary catheters and ureteral stents, Pellethane with and without surfacetreatment with HEMA or tetraglyme reduces encrustation in an artificial urine model. METHODS: 1048 patients,including 596 males and 452 females, who underwent uninephrectomy from June 2010 to June 2016 at the age of 16-87 years old with average of 58.7 years old,were followed up for 0.5-6.0 years, averaged of 3.2 years.532 patients combined with components of metabolic syndrome and 213 patients with metabolic syndrome.164 patients had a history of urolithiasis. The incidence of urinary stone formation in the contralateral kidney after uninephrectomy was recorded and analyzed. The urolithiasis incidences in different gender,age,comorbidity and history of urolithiasis patients after uninephrectomy were compared.
RESULTS: Eighty nine patients suffered from urinary stones in the contralateral kidney after uninephrectomy. The incidence of urinary stone formation in the contralateral kidney of uninephrectomy patients was 8.5%(89/1048), higher than in general population of China, which was 1%~5%. The urolithiasis incidence was 9.1%(54/596)in male patients after uninephrectomy and 7.7%(35/452)in female patients. The incidence of urinary stone formation was 8.6%(3/35)in patients aged under 30 years old,12.5%(34/272)in patients aged 30-49 years old,7.3%(37/504)in patients aged 50 to 69 years old,6.3%(15/237)in patients aged 70 years old and over. The incidence of urinary stone formation was 12.2%(65/532)in patients with components of metabolic syndrome after uninephrectomy and 19.7%(42/213)in patients with metabolic syndrome, while the incidence was 4.7%(24/516)in patients without components of metabolic syndrome. In patients with history of urolithiasis, the incidence was up to 30.5%(50/164)after uninephrectomy, while 4.4%(39/884)in patients without history of urolithiasis.
CONCLUSIONS: The incidence of urinary stone formation in the contralateral kidney of uninephrectomy patients was higher, especially in patients with metabolic syndrome or urolithiasis history. Uninephrectomy patients are more vulnerable to urolithiasis. . 199, No. 4S, Supplement, Friday, May 18, 2018 
